Media ReleasesImpediMed

View All ImpediMed News


ImpediMed - Appendix 4C & Quarterly Activities Report


ImpediMed Limited (ASX.IPD) today released its Appendix 4C – Quarterly Cash Flow report for the period ended 30 September 2021. A summary of the quarterly results was released on 27 October 2021 as part of the Capital Raising Presentation.

Highlights

Quarterly Results

• Total Revenue for Q1 FY’22 of $2.6 million, +71% on the previous corresponding period (pcp).
• Record quarter for SOZO® Revenue for Q1 FY’22 of $2.5 million, +76% pcp.
• Record quarter for cash receipts of $2.5 million.
• Largest US customer renewed SOZO agreement for an additional 3 years, integrating SOZO into their EPIC EHR system.
• Corporate Accounts:
-- ICON Group contract for initial 13 units.
-- Advocate Aurora Health imitated Heart Failure program.

Subsequent Events

• PREVENT Results Released:
-- Primary endpoint met with statistical and clinical significance achieved.
• AstraZeneca (AZ) contract extension and expansion – estimated value of over $500k in additional revenue to be recognised in coming quarters.
• Capital Raising:
-- $35 million Placement to new and existing institutional and sophisticated investors, increasing the pro forma cash balance to approximately $48 million, net of fees.
-- Sufficient capital raised to achieve breakeven while still allowing for investment in key growth initiatives.
-- Additional $5 million Share Purchase Plan (SPP) announced for eligible shareholders.

Revenue Summary:

• Total Revenue for Q1 FY’22 of $2.6 million, +71% pcp (Q1 FY’21: $1.5 million) and +1% quarter over quarter.
• Record quarter for SOZO® Revenue for Q1 FY’22 of $2.5 million, +76% pcp (Q1 FY’21: $1.4 million) and +8% quarter over quarter.
• Record quarter for SOZO SaaS Revenue for Q1 FY’22 of $2.1 million, +95% pcp and +10% quarter over quarter.
-- SOZO SaaS Revenue of $1.3 million from Core Business.
-- SOZO SaaS Revenue of $0.8 million from Clinical Business.

Cash Flow Summary:

• Cash on hand as at 30 September 2021 of $15.4 million.
• Record quarter for cash receipts from customers of $2.5 million.
• Net operating cash outflows for the quarter of $3.3 million.
• Related Parties: During the quarter, the Company Directors received a combination of cash remuneration, as well as issued shares as equity-based remuneration in lieu of cash, as described in Item 6 of the Appendix 4C.
• These payments to directors consisted of cash payments of $63,000 as well as $89,000 in Directors’ fees accrued and unpaid at 30 September 2021 related to equity-based remuneration.

For more information, download the attached PDF.

Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.